1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA
Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Annual Report to Security Holders
Amendment No. 3 to Equity Distribution Agreement with Piper Sandler
Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
Investor Presentation
Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
Announces $250.0 Million Registered Offering of Common Stock
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Free Writing Prospectus
Submission Upload
Correspondence